drugset

drugset / Trial / NCT06662942

StrataMGT in the Reduction of Vulvar Lichen Sclerosus (LS) Symptoms

NCT06662942 ↗

Phase 1 Recruiting 100 enrolled Andrew T. Goldstein, MD Stratpharma AG · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to evaluate the efficacy and safety of StrataMGT for the management of vulvar lichen sclerosus symptoms.

Timeline

Start: 2024-10-16
Primary completion: 2025-10-16
Completion: 2025-10-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	StrataMGT	Unknown	—	Topical

Indications